Lynette Williams Cholangiocarcinoma Journey
Lynette and John Williams cholangiocarcinoma story of early detection, liver resection, recurrence and structured response under pressure.
Joe & Tegan’s Cholangiocarcinoma Journey
Joe and Tegan’s cholangiocarcinoma story shows how truth, ownership and response can change trajectory through diagnosis, crisis and recurrence.
Jill Brown Cholangiocarcinoma | Podcast on losing her daughter Catie
Listen to the Jill Brown cholangiocarcinoma podcast as she shares losing her daughter Catie at 22 and reflects on grief and resilience.
Bridging Funding Australia Why Approved Medicines Take 466 Days to Reach Patients
Australia approves medicines that patients cannot access for an average of 466 days. This article explains why the delay exists, what bridging funding is, and why it matters to patients and caregivers.
ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Lisa Craine – Cholangiocarcinoma Patient
Lisa Craine -Cholangiocarcinoma patient. Lisa speaks at the 2017 CCF [...]
Lynette Williams Cholangiocarcinoma Journey
Lynette and John Williams cholangiocarcinoma story of early detection, liver resection, recurrence and structured response under pressure.
Joe & Tegan’s Cholangiocarcinoma Journey
Joe and Tegan’s cholangiocarcinoma story shows how truth, ownership and response can change trajectory through diagnosis, crisis and recurrence.
Jill Brown Cholangiocarcinoma | Podcast on losing her daughter Catie
Listen to the Jill Brown cholangiocarcinoma podcast as she shares losing her daughter Catie at 22 and reflects on grief and resilience.
Bridging Funding Australia Why Approved Medicines Take 466 Days to Reach Patients
Australia approves medicines that patients cannot access for an average of 466 days. This article explains why the delay exists, what bridging funding is, and why it matters to patients and caregivers.
ATM Mutation in Cancer: Context Before Conclusions
If ATM has appeared in your genetic or tumour reports, this article explains what ATM mutation in cancer really means, how it relates to MMR and BRCA1/2, and why biological context matters far more than the gene name alone.
Lisa Craine – Cholangiocarcinoma Patient
Lisa Craine -Cholangiocarcinoma patient. Lisa speaks at the 2017 CCF [...]
